QUOTED. 14 January 2020. Marshall Stanton.
Medtronic said it will acquire Stimgenics, which developed a differential target multiplexed spinal cord stimulation waveform, for an undisclosed figure. See what Marshall Stanton, who heads up Medtronic's pain therapy business, said about it here.
Stimgenics’ DTM waveform represents “the first time that a group of scientists or any company has started with a basic-science potential mechanism and developed a waveform and approach to alleviate pain based on that basis science.” – Marshall Stanton, president, Medtronic's pain therapy business
Click here for a free trial of Medtech Insight